NEUROPHET, Inc. (380550.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
5,300.00 KRW
Market cap
64.09 bn KRW
P/E (2025)
–
P/S (2025)
24.51
Dividend yield
0.00 %
Net margin
-856.15 %
Return on equity (ROE)
-115.10 %
Return on assets (ROA)
-83.28 %

NEUROPHET, Inc. financials

Fiscal year20242025
Revenue2.22 bn KRW2.62 bn KRW
Gross profit2.22 bn KRW2.62 bn KRW
Operating income-14.65 bn KRW-16.55 bn KRW
EBIT-11.49 bn KRW-21.47 bn KRW
Net income-15.10 bn KRW-22.39 bn KRW
Diluted EPS – continuing operations-1,315.91 KRW-1,851.59 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About NEUROPHET, Inc.

NEUROPHET, Inc., operates as a neuroscience company, engages in the development of medical artificial intelligence solutions in the field of brain science and diseases. The company offers Neurophet AQUA, AI-powered diagnosis assistant software for brain diseases; Neurophet SCALE PET, a software that quantitatively analyzes biomarkers targeted by a specific radiotracer using PET; Neurophet tES LAB, AI-Powered software to generate a 3D model using brain MRI and simulate electrical stimulation for treatment planning; and Neurophet innk, a non-invasive electrical stimulation device designed to aid in the functional recovery and rehabilitation of patients with brain diseases. It also provides Consulting services for design systems and quality management systems. The company has a strategic collaboration with VHIR Vall d'Hebron Institut de Recerca for the development of AI algorithms that detect multiple sclerosis lesions using MRI data. The company was founded in 2016 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.